Leveraging genome-wide data to investigate differences between opioid use vs. opioid dependence in 41,176 individuals from the Psychiatric Genomics Consortium.

Journal Article (Journal Article)

To provide insights into the biology of opioid dependence (OD) and opioid use (i.e., exposure, OE), we completed a genome-wide analysis comparing 4503 OD cases, 4173 opioid-exposed controls, and 32,500 opioid-unexposed controls, including participants of European and African descent (EUR and AFR, respectively). Among the variants identified, rs9291211 was associated with OE (exposed vs. unexposed controls; EUR z = -5.39, p = 7.2 × 10-8). This variant regulates the transcriptomic profiles of SLC30A9 and BEND4 in multiple brain tissues and was previously associated with depression, alcohol consumption, and neuroticism. A phenome-wide scan of rs9291211 in the UK Biobank (N > 360,000) found association of this variant with propensity to use dietary supplements (p = 1.68 × 10-8). With respect to the same OE phenotype in the gene-based analysis, we identified SDCCAG8 (EUR + AFR z = 4.69, p = 10-6), which was previously associated with educational attainment, risk-taking behaviors, and schizophrenia. In addition, rs201123820 showed a genome-wide significant difference between OD cases and unexposed controls (AFR z = 5.55, p = 2.9 × 10-8) and a significant association with musculoskeletal disorders in the UK Biobank (p = 4.88 × 10-7). A polygenic risk score (PRS) based on a GWAS of risk-tolerance (n = 466,571) was positively associated with OD (OD vs. unexposed controls, p = 8.1 × 10-5; OD cases vs. exposed controls, p = 0.054) and OE (exposed vs. unexposed controls, p = 3.6 × 10-5). A PRS based on a GWAS of neuroticism (n = 390,278) was positively associated with OD (OD vs. unexposed controls, p = 3.2 × 10-5; OD vs. exposed controls, p = 0.002) but not with OE (p = 0.67). Our analyses highlight the difference between dependence and exposure and the importance of considering the definition of controls in studies of addiction.

Full Text

Duke Authors

Cited Authors

  • Polimanti, R; Walters, RK; Johnson, EC; McClintick, JN; Adkins, AE; Adkins, DE; Bacanu, S-A; Bierut, LJ; Bigdeli, TB; Brown, S; Bucholz, KK; Copeland, WE; Costello, EJ; Degenhardt, L; Farrer, LA; Foroud, TM; Fox, L; Goate, AM; Grucza, R; Hack, LM; Hancock, DB; Hartz, SM; Heath, AC; Hewitt, JK; Hopfer, CJ; Johnson, EO; Kendler, KS; Kranzler, HR; Krauter, K; Lai, D; Madden, PAF; Martin, NG; Maes, HH; Nelson, EC; Peterson, RE; Porjesz, B; Riley, BP; Saccone, N; Stallings, M; Wall, TL; Webb, BT; Wetherill, L; Psychiatric Genomics Consortium Substance Use Disorders Workgroup, ; Edenberg, HJ; Agrawal, A; Gelernter, J

Published Date

  • August 2020

Published In

Volume / Issue

  • 25 / 8

Start / End Page

  • 1673 - 1687

PubMed ID

  • 32099098

Pubmed Central ID

  • PMC7392789

Electronic International Standard Serial Number (EISSN)

  • 1476-5578

Digital Object Identifier (DOI)

  • 10.1038/s41380-020-0677-9


  • eng

Conference Location

  • England